PrzemysÅ‚aw JuszczyÅ„ski

List of Publications by Year
in descending order

107 papers	4,187 citations	257357 24 h-index	114418 63 g-index
113 all docs	113 docs citations	113 times ranked	6465 citing authors

#	Article	IF	Citations
1	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, 2010, 116, 3268-3277.	0.6	1,122
2	Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy. Clinical Cancer Research, 2012, 18, 1611-1618.	3.2	582
3	The AP1-dependent secretion of galectin-1 by Reedâ€“Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13134-13139.	3.3	299
4	SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood, 2008, 111, 2230-2237.	0.6	289
5	SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas. Cancer Cell, 2013, 23, 826-838.	7.7	152
6	BBAP Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response. Molecular Cell, 2009, 36, 110-120.	4.5	133
7	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3207-3212.	3.3	130
8	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood, 2007, 110, 2067-2074.	0.6	117
9	BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate. Molecular and Cellular Biology, 2006, 26, 5348-5359.	1.1	107
10	Protein tyrosine phosphatase receptorâ€“type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cellâ€“receptor signaling, and cellular proliferation. Blood, 2006, 108, 3428-3433.	0.6	86
11	Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood, 2002, 100, 3037-3040.	0.6	78
12	Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood, 2011, 117, 4315-4322.	0.6	75
13	AP1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features. Clinical Cancer Research, 2008, 14, 3338-3344.	3.2	67
14	FOXO1 Transcription Factor: A Critical Effector of the PI3K-AKT Axis in B-Cell Development. International Reviews of Immunology, 2014, 33, 146-157.	1.5	63
15	FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood, 2016, 127, 739-748.	0.6	54
16	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood, 2009, 114, 5315-5321.	0.6	53
17	Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy. Clinical Epigenetics, 2020, 12, 147.	1.8	49
18	MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 457-467.	3.3	42

#	Article	IF	Citations
19	FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. Oncogene, 2016, 35, 5989-6000.	2.6	42
20	Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood, 2017, 130, 1418-1429.	0.6	42
21	MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1. Clinical Cancer Research, 2010, 16, 2122-2130.	3.2	39
22	Serine Biosynthesis Pathway Supports MYCâ€“miR-494â€“EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells. Cancers, 2020, 12, 580.	1.7	33
23	The heat shock protein 90 inhibitor IPIâ€504 induces apoptosis of AKTâ€dependent diffuse large Bâ€cell lymphomas. British Journal of Haematology, 2009, 144, 358-366.	1.2	30
24	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. PLoS ONE, 2016, 11, e0155893.	1.1	26
25	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget, 2018, 9, 16917-16931.	0.8	25
26	New insights into redox homeostasis as a therapeutic target in B-cell malignancies. Current Opinion in Hematology, 2017, 24, 393-401.	1.2	24
27	Targeting the thioredoxin system as a novel strategy against Bâ€cell acute lymphoblastic leukemia. Molecular Oncology, 2019, 13, 1180-1195.	2.1	24
28	Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. Genes Chromosomes and Cancer, 2007, 46, 500-507.	1.5	23
29	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. OncoImmunology, 2018, 7, e1423183.	2.1	23
30	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica, 2020, 105, 1361-1368.	1.7	23
31	SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. Cell Death and Disease, 2020, 11, 956.	2.7	20
32	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Research, 2021, 81, 6029-6043.	0.4	20
33	Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia. Molecular Medicine Reports, 2015, 11, 3948-3954.	1.1	18
34	Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements. Blood, 2008, 112, 2539-2539.	0.6	18
35	Repetitive genomic elements and overall DNA methylation changes in acute myeloid and childhood B-cell lymphoblastic leukemia patients. International Journal of Hematology, 2014, 100, 79-87.	0.7	17
36	Microenvironmentâ€induced PIM kinases promote CXCR 4â€triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration. Journal of Cellular and Molecular Medicine, 2018, 22, 3548-3559.	1.6	17

#	Article	IF	Citations
37	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs, 2014, 6, 1300-1313.	2.6	16
38	Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients. Leukemia Research, 2014, 38, 850-856.	0.4	16
39	PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-ÎºB Activity. American Journal of Pathology, 2021, 191, 567-574.	1.9	16
40	Comparison of highâ€resolution melting analysis with direct sequencing for the detection of recurrent mutations in <scp>DNA</scp> methyltransferase 3<scp>A</scp> and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients. European Journal of Haematology, 2016, 96, 181-187.	1.1	14
41	MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells. Experimental Hematology, 2017, 46, 56-61.e1.	0.2	13
42	Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia. Haematologica, 2007, 92, 710-711.	1.7	12
43	BRAF inhibition curtails IFNâ€gammaâ€inducible PDâ€L1 expression and upregulates the immunoregulatory protein galectinâ€1 in melanoma cells. Molecular Oncology, 2020, 14, 1817-1832.	2.1	12
44	Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkinâ€™s lymphoma outcome. Tissue Antigens, 2007, 71, 071029015950001-???.	1.0	11
45	Expression of the Multidrug Resistance-associated Protein (mrp) Gene in Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2002, 43, 153-158.	0.6	10
46	Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) withPCM1â€“JAK2fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?. Leukemia and Lymphoma, 2012, 53, 1824-1827.	0.6	9
47	Host immune response in B-cell lymphomas: friend or foe?. Archivum Immunologiae Et Therapiae Experimentalis, 2008, 56, 245-255.	1.0	8
48	Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. Haematologica, 2018, 103, 1843-1852.	1.7	8
49	Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188697.	3.3	8
50	DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells. Experimental Hematology, 2020, 88, 56-67.e2.	0.2	7
51	Tonic B-Cell Receptor Signaling Promotes the Survival of Diffuse Large B-Cell Lymphomas: Identification of SYK as a Rational Treatment Target.. Blood, 2006, 108, 226-226.	0.6	6
52	MiR-155 Amplifies AKT and NFkB Signaling By Targeting Multiple Regulators of BCR Signal in DLBCL. Blood, 2015, 126, 2455-2455.	0.6	6
53	B-Aggressive Lymphoma Gene (BAL) Is a Risk-Related, Î³IFN-Inducible Gene That Is Expressed in Primary Diffuse Large B-Cell Lymphomas with a Brisk Host Inflammatory Response.. Blood, 2004, 104, 2035-2035.	0.6	5
54	Comparison Study for Genotyping of a Single-Nucleotide Polymorphism in the Tumor Necrosis Factor Promoter Gene. Diagnostic Molecular Pathology, 2002, 11, 228-233.	2.1	4

#	Article	IF	Citations
55	The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients. Journal of Clinical Medicine, 2021, 10, 2683.	1.0	4
56	Microenvironment-Induced Expression of PIM Kinases Supports Chronic Lymphocytic Leukemia Cells Survival and Promotes CXCR4-mTOR Pathway Dependent Migration. Blood, 2016, 128, 3239-3239.	0.6	4
57	The Role of Major Histocompatibility Complex Polymorphisms in the Incidence and Outcome of Non-Hodgkin Lymphoma. Current Immunology Reviews, 2009, 5, 300-310.	1.2	3
58	BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation. Annals of Oncology, 2018, 29, viii463-viii464.	0.6	3
59	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. Scientific Reports, 2021, 11, 10017.	1.6	3
60	Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. European Journal of Haematology, 2021, 106, 320-326.	1.1	2
61	Abstract 1749: Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies. Cancer Research, 2014, 74, 1749-1749.	0.4	2
62	A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity. Blood, 2015, 126, 706-706.	0.6	2
63	Downregulation of Deptor By MiR-155 Promotes Cell Survival through Activation of PI3K/AKT and NFkB Signaling in ABC-Type Diffuse Large B-Cell Lymphomas. Blood, 2016, 128, 1761-1761.	0.6	2
64	SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial. Blood, 2019, 134, 2651-2651.	0.6	2
65	Correction: Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy: Figure 3.. Clinical Cancer Research, 2012, 18, 2117-2117.	3.2	1
66	Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease. Leukemia and Lymphoma, 2016, 57, 1471-1473.	0.6	1
67	An immunomagnetic cell separation system based on a retroviral vector containing a chimeric, recombinant human-murine CD4 gene. Central-European Journal of Immunology, 2018, 43, 353-357.	0.4	1
68	Abstract 1306: SEL120, a potent and specific inhibitor of CDK8 induces complete remission in human patient derived xenograft models of acute myeloid leukemia. , 2019, , .		1
69	BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.. Blood, 2006, 108, 225-225.	0.6	1
70	Hodgkinâ€™s Lymphoma Reed Sternberg Cells over Express the T-Cell Inhibitory Carbohydrate-Binding Lectin, Galectin 1: Role of AP-1 and Likely Mechanism of Tumor Immune Escape.. Blood, 2006, 108, 469-469.	0.6	1
71	The BBAP E3 Ligase Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response in Chemotherapy-Resistant Lymphomas.. Blood, 2009, 114, 3958-3958.	0.6	1
72	CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 631-631.	0.6	1

#	Article	IF	Citations
73	FOXO1-p300-Txn Circuit Regulates Oxidative Stress Responses in Diffuse Large B-Cell Lymphomas Characterized By Enhanced Oxidative Phosphorylation. Blood, 2015, 126, 466-466.	0.6	1
74	Nowe cele terapii ukierunkowanej w nowotworach ukÅ‚adu chÅ‚onnego z perspektywy ostatnich 5 lat badaÅ„. Hematologia, 2015, 6, 1-9.	0.0	1
75	Abstract 5394: First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for the treatment of hematological malignancies. Cancer Research, 2015, 75, 5394-5394.	0.4	1
76	Molekularna patogeneza przewlekÅ‚ej biaÅ‚aczki limfocytowej. Hematologia, 2017, 7, 273-286.	0.0	1
77	PIM Kinase Inhibition Decreases the Proangiogenic Properties of Multiple Myeloma Cells and Affects the Metabolic State of the Vascular Endothelium. Blood, 2020, 136, 16-17.	0.6	1
78	SIRT1 and HSP90alpha Are Functionally Linked and Control Mitotic Chromosome Segregation and Cell Viability in a Subset of Dlbcls. Blood, 2020, 136, 28-29.	0.6	1
79	Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients. Experimental Hematology, 2013, 41, S27.	0.2	0
80	Protein Tyrosine Phosphatase Receptor-Type O Truncated (PTPROT) Regulates SYK Phosphorylation, Proximal B-Cell Receptor Signaling and Cellular Proliferation.. Blood, 2006, 108, 933-933.	0.6	0
81	Heat Shock Protein 90 (HSP90) Is a Rational Therapeutic Target in Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 829-829.	0.6	0
82	A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 616-616.	0.6	0
83	BCL6 Regulates Tonic BCR Signaling in Diffuse Large B-Cell Lymphomas by Repressing the SYK Phosphatase, PTPROt. Blood, 2008, 112, 802-802.	0.6	0
84	Expression and Targeted Inhibition of the Immunoregulatory Carbohydrate-Binding Lectin, Galectin 1, in EBV-Driven Post-Transplant Lymphoproliferative Disorders.. Blood, 2009, 114, 96-96.	0.6	0
85	Molecular Pathogenesis of Aggressive B-cell Lymphomas. Principles and Practice, 2012, , 55-70.	0.3	0
86	Gene Expression Profiling in Hematologic Malignancies. Principles and Practice, 2012, , 199-214.	0.3	0
87	HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications. Blood, 2015, 126, 1436-1436.	0.6	0
88	FOXO1 Activation Is an Effector of SYK and AKT Inhibition in Tonic BCR Signal-Dependent Diffuse Large B-Cell Lymphomas. Blood, 2015, 126, 314-314.	0.6	0
89	Activity of PIM Kinases in Chronic Lymphocytic Leukemia Modulates Tumor Cell Survival and Stromal Interactions through a Pleiotropic Mechanism Involving Modulation of CXCR4 - mTOR Pathway. Blood, 2015, 126, 1549-1549.	0.6	0
90	Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma. Blood, 2015, 126, 819-819.	0.6	0

#	Article	IF	Citations
91	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. Blood, 2015, 126, 4917-4917.	0.6	0
92	Rodzina onkogennych kinaz PIM â€" potencjalne cele terapeutyczne w nowotworach ukÅ‚adu krwiotwÃ³rczego i chÅ‚onnego. Nowotwory, 2016, 66, 1-11.	0.1	0
93	Functional Link Between Heat Shock Protein HSP90alpha and Sirtuin 1 (SIRT1) in the Pathogenesis of Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 4120-4120.	0.6	0
94	Instytut Hematologii i Transfuzjologii â€" nowatorskie rozwiÄ…zania polegajÄ…ce na kompleksowoÅ›ci, koordynacji, innowacyjnoÅ›ci i jakoÅ›ci w celu poprawy diagnostyki i leczenia, komfortu chorego i postÄ™pu w medycynie. Hematologia, 2017, 7, 173-216.	0.0	0
95	Abstract 4087: Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies. , 2017, , .		0
96	Abstract B17: FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies. , 2018, , .		0
97	CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human Acute Myeloid Leukemia Models. Blood, 2018, 132, 1520-1520.	0.6	0
98	Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib. Blood, 2019, 134, 5456-5456.	0.6	0
99	CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation. Blood, 2019, 134, 3774-3774.	0.6	0
100	Mechanizmy dziaÅ‚ania i strategie opornoÅ›ci komÃ³rek nowotworowych przeciwko apoptozie indukowanej przez TRAIL. Hematologia, 2019, 10, 135-147.	0.0	0
101	Perspektywy rozwoju strategii terapeutycznych opartych na TRAIL i jego analogach w hematoonkologii. Hematologia, 2019, 10, 148-160.	0.0	0
102	Abstract 6217: Synergistic effect of CDK8 and BCL-2 inhibition in AML through regulation of MCL-1 and BIM balance. , 2020, , .		0
103	RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation. Blood, 2021, 138, 1518-1518.	0.6	0
104	Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML. Blood, 2021, 138, 2371-2371.	0.6	0
105	Persistent imbalance, anti-apoptotic, and anti-inflammatory signature of circulating C-C chemokines and cytokines in patients with paroxysmal nocturnal hemoglobinuria. Cytokine, 2022, 150, 155780.	1.4	0
106	Hodgkin Lymphoma Reed-Sternberg Cells Induce Immunosuppressive and Pro-Angiogenic Phenotype of Tumor-Associated Macrophages in a Paracrine Manner. Blood, 2020, 136, 30-30.	0.6	0
107	Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. Blood, 2020, 136, 33-34.	0.6	0